INO Stock Analysis: Buy, Sell, or Hold?
INO - Inovio Pharmaceuticals, Inc.
$1.13
-0.61 (-35.06%)
▼
5d:
-27.1%
30d:
-34.68%
90d:
-35.06%
WAIT
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
INO is down 28.4% this week, but smart money is accumulating calls. Top strike: $2 2026-05-15 with 3,037 OI. Call ratio: 92% View Scanner →
Strength: 10.0/10
Get Alerted When INO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INO is down 27.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INO is down 27.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INO is currently trading at $1.13, which is considered oversold relative to its 30-day fair value range of $1.54 to $1.81.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $1.08, while resistance sits at $1.78. Short-term momentum is weak, with the stock down 35.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.63 (+575.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INO is in a downtrend. Immediate support is located at $1.08, while resistance sits at $1.78. Short-term momentum is weak, with the stock down 35.1% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.63 (+575.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.54 -
$1.81
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-35.1%)
- BULLISH: Trading 575.5% below Wall St target ($7.63)
- WARNING: Recommendation downgraded due to -27.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.54 -
$1.81
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.79
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.75
Wall Street Target
$7.63
(+575.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 02, 2026 10:13 PM ET
Data refreshes hourly during market hours. Next update: 11:13 PM
Data refreshes hourly during market hours. Next update: 11:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 53 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 53 HOLD |
